BRIEF published on 07/06/2026 at 22:10, 3 months 25 days ago Abivax Completes its $920 Million Public Offering Biotechnology Actions Funding Abivax Public Offering
BRIEF published on 07/06/2026 at 22:10, 3 months 25 days ago Abivax Secures $920 Million in Public Offering Biotechnology Abivax Ulcerative Colitis Public Offering American Depositary Shares
PRESS RELEASE published on 07/06/2026 at 22:05, 3 months 25 days ago Abivax Announces Closing of $920 Million Public Offering Abivax closes $920 million public offering, strengthening financial position. Proceeds to support operations until Q4 2029. Leerink Partners, Morgan Stanley, Piper Sandler, Guggenheim Securities involved in the offering Financial Position Abivax Morgan Stanley Public Offering Leerink Partners
BRIEF published on 07/02/2026 at 08:05, 3 months 30 days ago Abivax successfully concludes an ADS offer Biotechnology Abivax Offer Ads Investments
BRIEF published on 07/02/2026 at 08:05, 3 months 30 days ago Abivax's Offering Yields $920M Following Over-Allotment Exercise Biotechnology Abivax Obefazimod Capital Increase ADS Offering
PRESS RELEASE published on 07/02/2026 at 08:00, 3 months 30 days ago Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) Abivax announces full exercise of underwriters' option to purchase additional ADSs, bringing gross proceeds of offering to $920M (€807M) Biotechnology Abivax Capital Increase Underwriters ADSs
BRIEF published on 07/01/2026 at 15:17, 4 months ago Abivax resumes trading of its shares on Euronext Paris Euronext Paris Biotechnology Actions Abivax Suspension
BRIEF published on 07/01/2026 at 15:17, 4 months ago Abivax relaunches trading of its shares on Euronext Paris Euronext Paris Ordinary Shares Abivax Inflammatory Diseases American Depositary Shares
BRIEF published on 07/01/2026 at 14:59, 4 months ago Abivax Resumes Trading on Euronext Paris Euronext Paris Biotechnology Abivax Ulcerative Colitis American Depositary Shares
PRESS RELEASE published on 07/01/2026 at 14:54, 4 months ago Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces resumption of trading for its ordinary shares on Euronext Paris following a public offering in the United States Euronext Paris Abivax Public Offering Phase 3 Clinical Trials Trading Resumption
Published on 10/30/2026 at 23:35, 1 day 21 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 22 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 2 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 6 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 10 hours 58 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 16 hours 33 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 4 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 22 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 22 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 9 hours ago Capital increase through exercise of subscription rights
